EGFR-mutant NSCLC patients who exhibited clearance of EGFR mutant clones in ctDNA demonstrated benefits in PFS (HR: 0.30 [0.22, 0.41], 95% CI, I2 = 5%, P < .01). Here, EGFR is linked to non-small cell lung carcinoma.